Literature DB >> 26618396

Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized.

Hu Liu1,2, Shuang Geng1, Bo Wang1, Bing Wu2, Xiaoping Xie2, Shuang Wang2, Yiwei Zhong1, Xuanyi Wang1, Di Qu1, Yumei Wen1, Bin Wang1.   

Abstract

Chronic viral hepatitis B (CHB) is a major global health problem. A therapeutic vaccine for CHB comprised of yeast-derived recombinant HBsAg-anti-HBs immunogenic complexes (YIC) has been devloped by us. A series of clinical trials has shown its therapeutic efficacy in decreasing HBV viral load and converting serum HBeAg-positive to anti-HBe-positive status in a subpopulation of CHB patients. Herein, we present a study of the immuno-potentiating mechanisms of YIC revealed by live-cell imaging technology. We studied internalization and dissociation of YIC in cells in vitro, and antigen presentation and T cell stimulation in mice. We found that after YIC was internalized via the Fcγ receptors (FcγR) of antigen presenting cells, it was subsequently transferred through early and late endosomal into lysosomal compartments. The dissociation of YIC was mainly observed in the late endosome. Furthermore when YIC were injected into mice, the populations of IFN-γ- and TNF-α-producing CD8+ and CD4+ T cells were higher in the YIC group than in controls receiving antigen or antibody alone. These observations supplement the known mechanisms of YIC action as a therapeutic vaccine for CHB.

Entities:  

Keywords:  HBsAg-anti-HBs complex; chronic hepatitis B; cross-presentation; dendritic cells; therapeutic vaccine

Mesh:

Substances:

Year:  2016        PMID: 26618396      PMCID: PMC4962741          DOI: 10.1080/21645515.2015.1072660

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

1.  Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.

Authors:  Danita H Schuurhuis; Andreea Ioan-Facsinay; Bas Nagelkerken; Jolien J van Schip; Christine Sedlik; Cornelis J M Melief; J Sjef Verbeek; Ferry Ossendorp
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

2.  Phagocytosis: how the phagosome became the phag-ER-some.

Authors:  Colin Watts
Journal:  Curr Biol       Date:  2002-10-01       Impact factor: 10.834

3.  Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients.

Authors:  Xin Yao; Bojian Zheng; Jie Zhou; Dao-Zhen Xu; Kai Zhao; Shu-Hui Sun; Zheng-Hong Yuan; Yu-Mei Wen
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

4.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

5.  Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy.

Authors:  Y M Wen; X H Wu; D C Hu; Q P Zhang; S Q Guo
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

6.  Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice.

Authors:  B J Zheng; M H Ng; L F He; X Yao; K W Chan; K Y Yuen; Y M Wen
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

7.  Efficient scavenger receptor-mediated uptake and cross-presentation of negatively charged soluble antigens by dendritic cells.

Authors:  Kohsuke Shakushiro; Yasuomi Yamasaki; Makiya Nishikawa; Yoshinobu Takakura
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

Review 8.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

9.  Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.

Authors:  A Regnault; D Lankar; V Lacabanne; A Rodriguez; C Théry; M Rescigno; T Saito; S Verbeek; C Bonnerot; P Ricciardi-Castagnoli; S Amigorena
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

10.  A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.

Authors:  Dao-Zhen Xu; Kai Zhao; Li-Min Guo; Lan-Juan Li; Qing Xie; Hong Ren; Ji-Ming Zhang; Min Xu; Hui-Fen Wang; Wen-Xiang Huang; Wen-Xiang Wang; Xue-Fan Bai; Jun-Qi Niu; Pei Liu; Xin-Yue Chen; Xin-Liang Shen; Zheng-Hong Yuan; Xuan-Yi Wang; Yu-Mei Wen
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  5 in total

1.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

Review 2.  Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.

Authors:  Jennifer Lambour; Mar Naranjo-Gomez; Marc Piechaczyk; Mireia Pelegrin
Journal:  Emerg Microbes Infect       Date:  2016-08-17       Impact factor: 7.163

3.  Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.

Authors:  Catarina E Hioe; Rajnish Kumar; Chitra Upadhyay; Muzafar Jan; Alisa Fox; Vincenza Itri; Kristina K Peachman; Mangala Rao; Lily Liu; Nathan C Lo; Michael Tuen; Xunqing Jiang; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

Review 4.  Immunoregulatory functions of immune complexes in vaccine and therapy.

Authors:  Yu-Mei Wen; Libing Mu; Yan Shi
Journal:  EMBO Mol Med       Date:  2016-10-04       Impact factor: 12.137

5.  A "sandwich" strategy for functional cure of chronic hepatitis B.

Authors:  Xuan-Yi Wang; Yu-Mei Wen
Journal:  Emerg Microbes Infect       Date:  2018-05-17       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.